Rheumatoid Arthritis
Cancer risk minimisation is a high priority for people with rheumatic diseases, as it is for the general population. Tumor necrosis factor inhibitors (TNFi) have a long history of association with…
Our reporters have been prolific in finding the hot abstracts, those that were most attended or those that are getting the most buzz on social media. Here are RheumNows #ACRbest abstract…
1 year ago
Large observational study of TNF use among patients with RA & cancer
Overall encouraging, no negative impact on survival
I'm kind of a TNF-truther on this; I don't think they cause ANY increased risk of malignancy
@RheumNow #ACR23 Abstr 1675 https://t.co/KRVlIFxhl8
1 year ago
Does TNFi use in pts with RA and early breast cancer affect survival?
TNFi did not affect overall survival or breast cancer specific survival compared to cDMARDs
Steroids did increase mortality
@RheumNow #ACR23 Abs#1675
1 year ago
No significant difference in overall survival in early stage breast cancer (BC) patients treated with TNFi (alone -/+ cDMARDs, in 1st year of BC) and cDMARDs in RA. Those on glucocorticoids had worse survival. Suarez-Almazor M, Abst#1675 #ACR23 @RheumNow https://t.co/lnZx3OpuN5
1 year ago
Insights into pathogenesis venous & arterial thrombosis in RA + JAKi
Significant dysregulation of clotting pathways in myeloid & increased clot formation in context of microbial challenge (TLR4)
Observed across all JAKI, but selective JAK3i
@RheumNow #ACR23 ABST1676 https://t.co/nboy0znfAW
Methotrexate (MTX) is widely used in rheumatic diseases yet poses common tolerance issues, especially for the oral form; and bioavailability is known to be limited for doses over 15mg.
Back in 2006…
Poster Hall